Hyperprolactinemia: Prolactin elevations may occur (.Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain (.Tardive Dyskinesia: Discontinue if clinically appropriate (.Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (.Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) (.It may be necessary to increase the dose of LATUDA ( Concomitant Use of a Moderate CYP3A4 Inducer:.Maximum recommended dose is 80 mg per day ( Recommended starting dose is 20 mg per day. LATUDA dose should be reduced to half of the original dose level.Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem):.The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day.Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day (.Schizophrenia –adolescents (13 to 17 years) (īipolar Depression –pediatric patients (10 to 17 years) (
Administration with food substantially increases the absorption of LATUDA ( LATUDA should be taken with food (at least 350 calories).
0 kommentar(er)
